Watch for details on the upcoming Part 2 oral maintenance study and any partnership or licensing interest from larger metabolic players. The Phase 3 readout timeline for VK2735 will be the next major catalyst.
Price Chart
Executive Summary
Viking Therapeutics announced positive topline results from its VK2735-102 maintenance study, demonstrating that patients transitioned from weekly to every-other-week or monthly dosing maintained up to 97% and 90% of weight loss, respectively, with GI adverse event rates similar to placebo. The 22% placebo-adjusted weight loss at Week 33 with no plateau observed further differentiates VK2735's pharmacokinetic profile. These data support flexible long-term dosing regimens that could improve adherence and competitive positioning against tirzepatide and semaglutide.
Key Facts
- Up to 97% of weight loss maintained after transition to every-other-week dosing for 12 weeks (p<0.0001 vs placebo).
- Up to 90% of weight loss maintained after transition to monthly dosing for 12 weeks (p=0.0002 vs placebo).
- 22% placebo-adjusted weight loss at Week 33 following weekly 17.5 mg dosing; no plateau observed.
- GI adverse event rates during maintenance phase were comparable to placebo.
- Discontinuation rates low: 1 subject (3%) in QOW group and 1 subject (2%) in monthly group discontinued due to adverse events.
- Company plans to explore oral maintenance dosing regimens in an upcoming part 2 of the study.
- VK2735 is currently being evaluated in Phase 3 clinical studies for obesity.
Financial Impact
Positive clinical data for VK2735 maintenance dosing could significantly enhance commercial prospects in the obesity market, potentially supporting premium pricing and higher adherence rates vs weekly competitors.
Risk Factors
- Phase 3 results may not replicate these Phase 2 maintenance findings.
- Competitive pressure from tirzepatide (Mounjaro/Zepbound) and semaglutide (Wegovy/Ozempic) with established market presence.
- Regulatory and manufacturing scale-up risks for both subcutaneous and oral formulations.
- Clinical-stage company with no approved products or revenue.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-397219 |
| Document: vktx-20260922.htm | 0001193125-26-397219 |
| Document: 0001193125-26-397219-index-headers.html | 0001193125-26-397219 |
| Document: 0001193125-26-397219-index.html | 0001193125-26-397219 |
| Document: 0001193125-26-397219.txt | 0001193125-26-397219 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | Institutional Cluster | $24.40 $24.21 | ▲ +0.78% | ▲ +1.49% | $24.89 (−2.01%) |
Oct 21, 2026 6d ago | Press Release | $25.83 $24.40 | ▼ −5.54% | ▼ −5.01% | $24.89 (−3.64%) |
Sep 28, 2026 29d ago | 8-K | $31.81 $32.60 | ▲ +2.48% | ▲ +2.69% | $24.89 (−21.75%) |
Sep 24, 2026 4w ago | 424B5 | $35.56 $33.03 | ▲ +7.11% | ▲ +6.37% | $24.89 (+30.01%) |
Sep 24, 2026 4w ago | 424B5 | $35.56 $33.03 | ▲ +7.11% | ▲ +6.37% | $24.89 (+30.01%) |
Sep 23, 2026 4w ago | 424B5 | $36.75 $35.56 | ▼ −3.24% | ▼ −3.78% | $24.89 (−32.27%) |
Sep 23, 2026 4w ago | 424B5 | $36.75 $35.56 | ▲ +3.24% | ▲ +3.78% | $24.89 (+32.27%) |
Sep 22, 2026 5w ago | 8-K | $40.85 $41.65 | ▲ +1.96% | ▲ +2.68% | $24.89 (−39.07%) |
Jul 29, 2026 12w ago | Insider Cluster | $33.11 $31.74 | ▼ −4.14% | ▼ −4.86% | $24.89 (−24.83%) |
Jul 29, 2026 12w ago | Insider Cluster | $33.11 $31.74 | ▼ −4.14% | ▼ −4.84% | $24.89 (−24.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers